Tirzepatide for Obesity and Meth Use Disorder

What Was Tested

In this phase 2 trial, researchers set out to test Tirzepatide.

It had 1 arm (groups): Tirzepatide (experimental).

Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 32-week period in accordance with FDA-prescribing label guidelines.

The registry classes the interventions as drug.

More on the Plan

Enrolled participants will receive weekly treatment with tirzepatide for a 32-week period that will be followed by 4-week-long observational follow-up.

Participants of this study will be seen for weekly visits where they will complete clinical and/or laboratory assessments.

Who Took Part

35 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Be 18 to 65 years of age, inclusive. Be able to provide informed consent and ask relevant questions. Stated willingness to comply with all study procedures and availability for the duration of the study. Be willing to adhere to the study medication regimen. Meet DSM-5 criteria for moderate or severe methamphetamine use disorder.

The full record lists 11 inclusion and 16 exclusion criteria; among the exclusions: current or recent use (within 3 months prior to consent) of other tirzepatide-containing products or any other glp-1 receptor agonist; current or recent use (within 30 days) of sulfonylureas, other concomitantly administered insulin secretagogue, or insulin; current or recent use (within 3 months prior to consent) of other weight loss agents.

How the Study Was Run

The set-up was single-group and open-label.

Being open-label, the Tirzepatide study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-02-03 with completion listed for 2026-02-12.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Effect of tirzepatide on self-reported use of methamphetamine (time frame: 36 weeks).

It also tracked 5 secondary outcomes, for example Feasibility of using tirzepatide in individuals with Methamphetamine Use Disorder, Changes in body mass index from baseline to the end of the 32-week treatment phase, Changes in self-reported symptoms of anhedonia from baseline to the end of the 32-week treatment phase, Changes in High-sensitivity C-reative protein (hs-CRP) levels from baseline to the end of the 32-week treatment phase and Changes in gastrointestinal symptom severity from baseline until the end of the 32-week treatment phase.

What This Means in Plain Language

Put simply, this is a phase 2 trial of Tirzepatide in 35 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.